Literature DB >> 17917681

The shadow of death on the MET tyrosine kinase receptor.

D Tulasne1, B Foveau.   

Abstract

The MET tyrosine kinase receptor is a high-affinity receptor for hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF-MET system is necessary for embryonic development, and aberrant MET signalling favours tumorigenesis and metastasis. MET is a prototype of tyrosine kinase receptor, which is able to counteract apoptosis through the initiation of a survival signal involving notably the PI3K-Akt pathway. Paradoxically, the MET receptor is also able to promote apoptosis when activated by HGF/SF or independently of ligand stimulation. The molecular mechanisms underlying this uncommon response have been recently investigated and revealed dual antiapoptotic or proapoptotic property of MET according to the cell type or stress conditions. Although the involvement of MET in the regulation of integrated biological responses mostly took into account its efficient antiapoptotic function, its proapoptotic responses could also be important for regulation of the survival/apoptosis balance and play a role during the development or tumour progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917681     DOI: 10.1038/sj.cdd.4402229

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  34 in total

1.  Growth factor- and cytokine-driven pathways governing liver stemness and differentiation.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

2.  Role of hepatocyte growth factor in the immunomodulation potential of amniotic fluid stem cells.

Authors:  Tullia Maraldi; Francesca Beretti; Marianna Guida; Manuela Zavatti; Anto De Pol
Journal:  Stem Cells Transl Med       Date:  2015-04-14       Impact factor: 6.940

3.  Novel proapoptotic effect of hepatocyte growth factor: synergy with palmitate to cause pancreatic {beta}-cell apoptosis.

Authors:  José A González-Pertusa; John Dubé; Shelley R Valle; Taylor C Rosa; Karen K Takane; José M Mellado-Gil; Germán Perdomo; Rupangi C Vasavada; Adolfo García-Ocaña
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

4.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

5.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Authors:  Mario Acunzo; Giulia Romano; Dario Palmieri; Alessandro Laganá; Michela Garofalo; Veronica Balatti; Alessandra Drusco; Mario Chiariello; Patrick Nana-Sinkam; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

6.  Clinical significance of pAKT and CD44v6 overexpression with breast cancer.

Authors:  Pei Yu; Ling Zhou; Weifeng Ke; Ke Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-16       Impact factor: 4.553

7.  Silencing of c-Met by RNA interference inhibits the survival, proliferation, and invasion of nasopharyngeal carcinoma cells.

Authors:  Yuncheng Li; Sulin Zhang; Zhengang Tang; Jian Chen; Weijia Kong
Journal:  Tumour Biol       Date:  2011-09-16

Review 8.  Novel therapy for liver regeneration by increasing the number of platelets.

Authors:  Kazuhiro Takahashi; Soichiro Murata; Nobuhiro Ohkohchi
Journal:  Surg Today       Date:  2012-11-21       Impact factor: 2.549

9.  Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.

Authors:  V W Y Lui; E Y L Wong; K Ho; P K S Ng; C P Y Lau; S K W Tsui; C-M Tsang; S-W Tsao; S H Cheng; M H L Ng; Y K Ng; E K Y Lam; B Hong; K W Lo; T S K Mok; A T C Chan; G B Mills
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 10.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.